Project description:To exploit targets or signaling pathways affected by PLS-123 during anti-tumor process, gene expression profiling was carried out in representative OCI-Ly7 cells treated for 48 hours. OCI-Ly7 cells were treated with ibrutinib, PLS-123 or vehicle for 48 hours.
Project description:To exploit targets or signaling pathways affected by PLS-123 during anti-tumor process, gene expression profiling was carried out in representative OCI-Ly7 cells treated for 24 hours.
Project description:To exploit targets or signaling pathways affected by PLS-123 during anti-tumor process, gene expression profiling was carried out in OCI-Ly7 inoculated xenograft model. Six- to eight-week-old male SCID mice were inoculated subcutaneously with OCI-Ly7 tumor cells in 0.1 ml PBS for tumor development
Project description:To exploit targets or signaling pathways affected by PLS-123 during anti-tumor process, gene expression profiling was carried out in OCI-Ly7 inoculated xenograft model.
Project description:DOT1L inhibition leads to a loss of H2AK119ub1 in different GC B-DLBCL cell lines. To determine whether this loss is global or gene specific, performed H2AK119ub1 and H3K27me3 CUT&Tag in the Oci-Ly7 cell line following six days of treatment with DMSO or DOT1Li. As reference, we used a doxycycline-inducible knockdown of USP7 due to its role in ncPRC1-mediated deposition of H2AK119ub1 in Oci-Ly7 cells.
Project description:To provide insight into the role of and target genes of the transcription factor FOXP1 in mature human B cells and in B cell non-Hodkgin lymhomas, we performed gene expression microarray studies, upon ectopic overexpression or silencing of FOXP1 in these cells. human memory B cells from 2 separate donors were transduced with LZRS-FOXP1-IRES-YFP or LZRS-IRES-YFP (negative control); DLBCL cell lines OCI-Ly1, OCI-Ly7, and OCI-Ly10 were transduced with LZRS-FOXP1-IRES-YFP or LZRS-IRES-YFP (negative control); DLBCL cell lines OCI-Ly1, OCI-Ly7, and OCI-Ly10 were transiently transfected with siRNA targeting FOXP1 or sigenome non-targeting siRNA (negative control), using the Lonza nucleofection system.
